Please login to the form below
ESMO
This page shows the latest ESMO news and features for those working in and with pharma, biotech and healthcare.
Merck closes in on adjuvant melanoma indication for Keytruda
At last year’s European Society for Medical Oncology (ESMO) congress, Bristol-Myers Squibb’s Opdivo (nivolumab) was found to be more effective than Yervoy (ipilimumab) - BMS’CTLA4 inhibitor which is
Latest news
-
Roche buys cancer company Ignyta for $1.7bn
It has breakthrough status from the FDA. Interim data from that study - reported at the European Society of Medical Oncology (ESMO) conference in September - showed that entrectinib achieved a response rate ... Entrectinib isn’t the only drug in
-
Data backs up Roche’s Tecentriq/Avastin combo in lung cancer
The data is being presented today at the European Society for Medical Oncology (ESMO) cancer immunotherapy congress in Geneva.
-
BMS adds another EU indication to Opdivo’s growing list
Researchers found Opdivo met its primary endpoint of recurrence-free survival and results were presented at the 2017’s European Society for Medical Oncology (ESMO) based in Madrid, Spain and simultaneously
-
Novartis scores but Roche misses in melanoma trials
The two studies reported at the European Society of Clinical Oncology (ESMO) congress in Madrid this week were carried out in high-risk, early-stage patients with stage III BRAF ... Both ipilimumab and the combination of dabrafenib plus trametinib have
-
Lilly's abemaciclib data leaves potential uncertain
The MONARCH 3 trial was reported at the European Society of Medical Oncology (ESMO) conference in Madrid over the weekend, and showed that the CDK4/6 inhibitor prolonged progression-free survival
More from news
Approximately 9 fully matching, plus 20 partially matching documents found.
Latest Intelligence
-
Biologic or biosimilar: what are prescribers thinking?
independent organisations such as ESMO, which recently published a paper supporting biosimilars as an option for sustainable cancer treatment.
-
Accelerating innovation
Phase II results from its CABOSUN trial, in which it was compared with Sutent in previously untreated advanced RCC, were released at this year’s European Society for Medical Oncology (ESMO) ... As the ESMO meeting began, Ipsen received the news that
-
Charting a course for expansion
When I met him at the annual European Society for Medical Oncology (ESMO) meeting in Copenhagen last month he explained how international expansion and oncology were key to Ipsen's plans. ... In Copenhagen, Ipsen's ESMO focus was on the CABOSUN study,
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Why patient education is important in oncology
Why patient education is important in oncology. We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
-
FALCON trial of fulvestrant for advanced breast cancer
FALCON trial of fulvestrant for advanced breast cancer. The Phase III FALCON trial compared fulvestrant to anastrozole for hormone receptor-positive advanced breast cancer. Summary/transcript. Prof. Matthew Ellis from the Baylor College of Medicine
-
No surprises: results from the ENGOT-OV16/NOVA trial of niraparib in ovarian cancer
We talked to Dr Ursula Matulonis of the Dana-Farber Cancer Institute, who co-authored the abstract presented at ESMO.
-
CABOSUN trial of cabozantinib – could it change how we treat frontline renal-cell carcinoma?
Dr Choueiri, who presented the results at ESMO 2016, explains, they also had an early look at overall survival (OS), which is not significant yet but trending in the right direction.
-
Why patient education is important in oncology
Why patient education is important in oncology. We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments has changed how patients need to be informed.
More from PMHub
Approximately 9 fully matching, plus 0 partially matching documents found.
Featured jobs
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Programme Executive
-
Salary TBC
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Senior Medical Writer
-
Great salary and benefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
-
Senior Medical Writer
-
Great salary and bebefits
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Account Manager – Med Comms – London
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
Subscribe to our email news alerts
PMHub
Dovetail
Transforming healthcare through effective collaboration. Making work to feel proud of.
www.dovetailstrategies.com...
Latest intelligence
- The Holy Grail of HCP Access
- This is the data you need to gain access....
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
Quick links
Infographics
